- International experts recommend screening children for early-stage type 1 diabetes from ages two to four.
- Repeat testing could identify children who develop signs of the condition later, before symptoms become obvious.
- The guidance is not an announcement of universal NHS screening, and testing must come with monitoring and family support.
Type 1 diabetes can begin long before thirst, weight loss or dangerously high blood glucose reveal that something is wrong.
New international guidance sets out how healthcare services could identify that earlier stage, giving families time to prepare rather than facing an emergency diagnosis.
Published in Diabetologia, the recommendations focus on blood tests for islet autoantibodies.
These are markers of the immune response directed against the pancreatic cells that produce insulin.
The proposed schedule starts between ages two and four.
Children who test negative would be screened again between six and eight, then between ten and 15, ideally alongside existing healthcare appointments.
A positive result would need confirmation. The presence of an autoantibody is not a reason to jump straight to a diagnosis or treatment decision.
Instead, repeat testing and an assessment of blood glucose would establish whether early-stage type 1 diabetes is present and what monitoring is needed. The distinction matters because the immune process and the loss of glucose control do not necessarily happen at the same time.
One of the main aims is to reduce diabetic ketoacidosis, or DKA, at diagnosis.
This potentially life-threatening complication can occur when insulin levels become dangerously low.
Detecting the condition earlier creates an opportunity to explain symptoms, monitor progression and discuss appropriate treatment or research options before a child becomes seriously unwell.
There is already relevant work under way in the UK. The ELSA study has been investigating childhood screening, with its next phase expanded to include children aged two to 17.
That is research into how screening could work, rather than a universal NHS programme already available through every GP surgery.
- New protective gel could help transplanted insulin-producing cells survive in type 1 diabetes
- Metformin may help some people with type 1 diabetes use less insulin
The new guidance is also clear that a screening service cannot stop at sending out blood-test results. Families need explanations, access to specialist advice and a reliable plan for follow-up.
Without that infrastructure, early detection could leave parents with understandable anxiety but little practical support.
The authors therefore recommend introducing screening only when services can deliver the entire pathway.
For families affected by type 1 diabetes, the significance is not simply an earlier label. It is the prospect of replacing some sudden, frightening diagnoses with a more informed and supported start to care.
